ClinicalTrials.gg
CompletedNCT02537444Updated Sep 25, 2019Results posted

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

A Phase 2 interventional study of Acalabrutinib and acalabrutinib and pembrolizumab combination in Ovarian Cancer, sponsored by Acerta Pharma BV. Completed at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing pembrolizumab in Ovarian Neoplasms — 7 open to participants now, 13 under way, 2 of them phase 3. pembrolizumab · Ovarian Neoplasms.

Enrollment
12th of 35
78 · median 38
Started
2015
with 1 other
Phase 2
26 of 35
5 open now
Registered
5th of 35
by date

Among the 35 studies testing pembrolizumab in Ovarian Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2015, is one of 26 in phase 2, and was the 5th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

7 of the 35 studies testing pembrolizumab in Ovarian Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing pembrolizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women ≥ 18 years of age.
  • confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
  • Progression of disease after the most recent anticancer treatment. At least 1 prior chemotherapy regimen must have included a taxane.
  • Platinum-sensitive ovarian cancer defined by recurrence or progression of disease > 6 AND \< 24 months after completion of the most recent platinum-based therapy.
  • as defined by 1.1.
  • performance status of 0 or 1.
  • Completion of all therapy for the treatment of cancer 2 weeks before the start of study therapy and recovered.

Exclusion criteria

Exclusion Criteria:

  • Evidence of platinum- ovarian cancer defined as recurrence or progression during the first 6 cycles of or \< 6 months after the beginning of platinum based chemotherapy.
  • Evidence of platinum-resistant ovarian cancer defined as recurrence or progression within 6 months after completing the most recent platinum-based therapy.
  • More than 3 prior lines of cytotoxic chemotherapy for ovarian cancer.
  • Prior (other than ovarian cancer), except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for ≥ 2 years or which will not limit survival to \< 2 years.
  • Breastfeeding and pregnant.
  • Known central nervous system and/or carcinomatous meningitis.
  • Subjects with active cardiovascular disease not medically controlled or those who have had myocardial infarction in the past 6 months..
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Regimen 1

    Drug: acalabrutinib monotherapy

    Drug: Acalabrutinib

  • Experimental
    Regimen 2

    Drug: Combination of acalabrutinib and pembrolizumab

    Drug: acalabrutinib and pembrolizumab combination

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Overall Response

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

    Time frame: Every 12 weeks for up to 2 years.

07

Results

Posted Sep 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneArm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
Started3939
Enrolled3939
Received study medication3839
Discontinued study3939
Completed00
Not completed3939

Outcome measures

PrimaryNumber of Participants With Overall Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR

Time frame:
Every 12 weeks for up to 2 years.
Reported as:
Count of participants · Participants
Number of Participants With Overall Response
ParticipantsArm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
Number of Participants With Overall Response13

Adverse events

Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1 - Acalabrutinib Monotherapy16/38 (42.1%)8/38 (21.1%)34/38 (89.5%)
Arm 2 - Acalabrutinib + Pembrolizumab22/39 (56.4%)16/39 (41%)39/39 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventArm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
Small Intestinal ObstructionGastrointestinal disorders1/385/39
Pleural EffusionRespiratory, thoracic and mediastinal disorders3/380/39
Alanine Aminotransferase IncreasedInvestigations1/383/39
Aspartate Aminotransferase IncreasedInvestigations1/383/39
Pericardial EffusionCardiac disorders1/380/39
VomitingGastrointestinal disorders1/380/39
PyrexiaGeneral disorders1/381/39
Non-Cardiac Chest PainGeneral disorders1/380/39
CellulitisInfections and infestations1/380/39
SepsisInfections and infestations1/380/39
Most frequent other events
Showing 10 of 83
Most frequent other events
EventArm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + Pembrolizumab
NauseaGastrointestinal disorders16/3829/39
VomitingGastrointestinal disorders7/3821/39
HeadacheNervous system disorders17/3821/39
FatigueGeneral disorders16/3820/39
DiarrheaGastrointestinal disorders17/3811/39
Abdominal PainGastrointestinal disorders9/3814/39
AnaemiaBlood and lymphatic system disorders2/3812/39
Alanine Aminotransferase IncreasedInvestigations4/3810/39
Decreased AppetiteMetabolism and nutrition disorders9/3810/39
CoughRespiratory, thoracic and mediastinal disorders3/3810/39

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Mean64.6 ± 11.5264.2 ± 12.7564.4 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Female383977
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
Hispanic or Latino134
Not Hispanic or Latino373673
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American134
White333467
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(participants)Arm 1 - Acalabrutinib MonotherapyArm 2 - Acalabrutinib + PembrolizumabTotal
United States383977
08

Study locations

2 sites
  • Arizona Gynecology Oncology
    Tucson, Arizona, United States
  • Jordan Center For Gynecologic Cancer At Penn
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jul 2018, 32 months.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 32 months is below that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2015
First posted
Sep 1, 2015
StartActual
Nov 2015
Primary completionActual
Jul 2018
CompletionActual
Oct 2018
Results first posted
Sep 12, 2019
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02537444
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Sep 1, 2015
Start date
Nov 2015
Primary completion
Jul 2018
Completion
Oct 2018
Results posted
Sep 12, 2019
Last update
Sep 25, 2019

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613; acertamc@dlss.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Pembrolizumab

Start the discussion